Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX)
· seekingalpha.com
CPRX Q1 2026 revenue surged as Firdapse and Agamree drive growth; Angelini’s $31.50 offer limits upside.
My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, ...